{"filings":[{"id":1647236,"accession_number":"0001827635-26-000023","cik":1827635,"company_name":"Veradermics, Inc","ticker":"MANE","form_type":"8-K","filed_at":"2026-07-15T12:54:36+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Veradermics: Phase 2 VDPHL01 shows 22.7-23.3 hairs/cm² increase, 88.9-90% improved at Month 6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean non-vellus hair count increase of 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily) at Month 6.","88.9% (once daily) and 90.0% (twice daily) of patients reported 'improved' or 'much improved' on AAIRS at Month 6.","Fast onset: 67.2% of participants graded by investigators as improved at Month 2, earliest measured time point.","No treatment-related SAEs or cardiac AESIs; common AEs were hypertrichosis and peripheral edema.","Topline results from Phase 2/3 Study '306' in female pattern hair loss expected in 1H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4254741318.9981036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22961,"accession_number":"0001827635-26-000016","cik":1827635,"company_name":"Veradermics, Inc","ticker":"MANE","form_type":"8-K","filed_at":"2026-05-12T12:32:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veradermics Q1 net loss $27.2M, positive Phase 2/3 results for VDPHL01 hair loss drug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.2M for Q1 2026 vs $12.4M Q1 2025; R&D $20.9M, G&A $8.9M.","Positive Phase 2/3 topline results for VDPHL01 in male pattern hair loss; 12-month data H2 2026.","Enrollment completed in Study '304' (Phase 3, male PHL); topline data H2 2026. Study '306' (female PHL) enrolling.","Raised ~$766.8M gross from IPO and follow-on; cash $390.8M at Mar 31, 2026, expected to fund into 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4254741318.9981036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95903,"accession_number":"0001628280-26-029376","cik":1827635,"company_name":"Veradermics, Inc","ticker":"MANE","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Veradermics raises $414M in public offering and private placement to Suvretta Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 3,843,790 shares at $100.00 per share, gross proceeds ~$384M.","Concurrent private placement: sold pre-funded warrants for 300,000 shares to Suvretta Capital affiliates for ~$30M.","Pre-funded warrants exercisable at $0.00001/share; 9.99% ownership cap (can be increased to 19.99% with 61 days notice).","Underwriters granted 30-day option to buy up to 576,568 additional shares at $100/share.","Company subject to 90-day lock-up on future share issuances (with customary exceptions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4254741318.9981036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95902,"accession_number":"0001628280-26-027629","cik":1827635,"company_name":"Veradermics, Inc","ticker":"MANE","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Veradermics reports preliminary cash of $390.8M as of March 31, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities total approximately $390.8 million as of March 31, 2026.","This amount is preliminary and subject to change upon completion of quarterly closing procedures.","Auditors Deloitte & Touche LLP have not audited or reviewed this preliminary data.","No other financial results (revenue, earnings) were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4254741318.9981036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95901,"accession_number":"0001628280-26-027354","cik":1827635,"company_name":"Veradermics, Inc","ticker":"MANE","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)","79.3% (QD) and 86.0% (BID) of patients reported improvement on AAIRS vs 35.6% placebo","No treatment-related serious adverse events or cardiac adverse events of special interest observed","Statistically significant separation from placebo observed as early as Month 2"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":4254741318.9981036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109320,"accession_number":"0001827635-26-000010","cik":1827635,"company_name":"Veradermics, Inc","ticker":"MANE","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veradermics reports FY 2025 net loss $70M; cash $141.9M; IPO raised $295M; two pivotal trials enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2025 net loss $70.0M vs $26.5M in 2024; Q4 net loss $21.8M vs $5.7M.","Cash, equivalents & marketable securities $141.9M at Dec 31, 2025; upsized IPO added $294.8M gross in Feb 2026.","R&D expenses FY 2025 $62.1M (up $38.8M YoY) driven by VDPHL01 clinical development and headcount.","Enrollment completed in Phase 2/3 Study 302 (male PHL) and confirmatory Study 304; topline data 1H and 2H 2026.","Appointed Mark Neumann as Chief Commercial & Strategy Officer; Study 306 enrolling for female PHL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4254741318.9981036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109319,"accession_number":"0001628280-26-005800","cik":1827635,"company_name":"Veradermics, Inc","ticker":"MANE","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Veradermics files amended charter and bylaws after IPO closing on Feb 5, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized 200M shares of common stock and 25M shares of undesignated preferred stock.","Eliminated prior preferred stock series and stockholder ability to act by written consent.","Amended bylaws establish procedures for stockholder proposals, director nominations, and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4254741318.9981036,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}